Nov 9 2008
Ellex Medical Lasers Limited, a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced the six-month clinical study results for the groundbreaking treatment Retina Regeneration Therapy (Ellex 2RT(TM)) at the annual meeting of the American Academy of Ophthalmology. The results were presented by Professor John Marshall, PhD, FRCPath, FRCOphth (Hons), of St. Thomas' Hospital, London, under whom the study has been conducted.
The six-month results show that Ellex 2RT is clinically safe and effective in the treatment of macular edema secondary to diabetic retinopathy.
"This is a revolutionary treatment because, for the first time, we can obtain all the therapeutic benefits seen with earlier laser treatments, but without the collateral damage," said Professor Marshall.
"Currently, this is the mildest laser therapy to be tested in a clinical setting which has demonstrated a selective and therapeutic effect on the retinal pigment epithelium (RPE)."
Ellex 2RT uses a custom designed, Q-switched green YAG laser that produces very precise, three-nanosecond pulses of 532nm light energy. The laser was developed specifically for Ellex 2RT by the Ellex Advanced Research Team in Adelaide, Australia.